Effects of a Low Dose of Oral Ademetionine (SAMe) on Behaviour and Quality of Life in Elderly Patients with Mild Mood Disorders
Ademetionine (SAMe) is a naturally occurring substance with proven antidepressant activity. This study assessed the effects of a low dose of ademetionine on behaviour and quality of life in elderly patients with mild mood disorders.
Design and study participants
In this open-label study, 198 elderly outpatients who approached their general practitioners reporting a nonspecific mood deterioration received oral ademetionine l00mg twice daily for 2 months. Patients’ response to treatment was assessed using a Behavioural and Quality Of Life (BQOL) self-assessment questionnaire and a Patient Evaluation of Therapy questionnaire.
Ademetionine significantly improved behaviour and quality of life over the 2-month treatment period (p < 0.001 vs baseline). Treatment compliance was high (97.3%) and no serious adverse events were reported.
Oral ademetionine l00mg twice daily is well tolerated and may improve behaviour and quality of life in elderly patients with mild mood disorders.
KeywordsHamilton Depression Rate Scale Score Endogenous Depression Tolerability Score Adenosyl Methionine Adenosyl Transferase
This study was supported by a grant from BioResearch SA, San Antonino, Switzerland, which also provided the study medication.
The following investigators participated in the study: R. Bardelli, Balerna, Switzerland; S. Bernasconi Coduri, Mendrisio, Switzerland; P. Bettelini-Lura, Riva S. Vitale, Switzerland; L. Binaghi, Coldrerio, Switzerland; M. Casartelli, Balerna, Switzerland; G. Ceracchini, Chiasso, Switzerland; R. Di Stefano, Pregassona, Switzerland; C. Folatti, Massagno, Switzerland; F. Fransioli, Airolo, Switzerland; G. Frey, Breganzona, Switzerland; M.E. Fritz, Castel S. Pietro, Switzerland; B. Galli, Losone, Switzerland; L. Genini, Paradiso, Switzerland; L. Heitmann, Chiasso, Switzerland; V. Manzocchi, Arzo, Switzerland; C. Poloni, Lugano, Switzerland; N. Realini, Chiasso, Switzerland; A. Rusca, Arzo, Switzerland. The author thanks Carlo Di Padova and Gabrielle Boissard for critical input, and Giovanna Bagnasco for editorial assistance.
- 2.Bottiglieri T. Ademetionine (S-adenosylmethionine) neuropharmacology: implications for drug therapies in psychiatric and neurological disorders. Expert Opin Invest Drugs 1997; 6:417–26Google Scholar
- 20.Caruso I, Fumagalli M, Bocassini L, et al. Treatment of depression in rheumatoid arthritic subjects: a comparison of S-adenosyl-methionine (Samyr) and placebo in a double blind study. Clin Trials J 1987; 24: 305–10Google Scholar
- 23.Pancheri P, Racagni G, Delle Chiaie R, et al. Recent experimental and clinical findings on the efficacy and safety of ademetionine in the pharmacological treatment of depression. G Ital Psicopatol 1997; 3: 1–23Google Scholar
- 26.American Psychiatric Association. DSM-IV: diagnostic and statistical manual of mental disorders. 4th ed. American Psychiatric Association: Washington, DC, 1994Google Scholar
- 31.Fava M, Rosenbaum JF. Transmethylation and the central nervous system. Acta Neurol Scand 1994; 89Suppl 154: 1–41Google Scholar